Friday, 21 Jul 2017

You are here

Anti-Sclerostin Drug Hampered by Heart Problems

Reuters reports that FDA approval of romosozumab (brand name Evenity) may be held up because of higher rates of cardiac events seen in a late-stage clinical trial.

Romosozumab is being codeveloped by Amgen and UCB who have released top-line results of the ARCH trial, a successful study in postmenopausal women with osteoporosis (OP).

Patients in the study received romosozumab for 12 months followed by alendronate, versus those on alendronate alone. Romosozumab was shown to significantly reduce vertebral and non-vertebral fractures through 24 months compared to alendronate.

However, an imbalance of serious heart problems were reported; 2.5 percent on romosozumab versus 1.9 in the alendronate group. Interestingly, no increased risk of cardiac events was seen in another pivotal trial, the placebo-controlled FRAME study (n=7180-patients). The company reports that other adverse events were equal between groups. 

"The efficacy results from this study comparing Evenity to an active control are robust. At the same time, the newly observed cardiovascular safety signal will have to be assessed as part of the overall benefit/risk profile for Evenity," Amgen research chief Sean Harper said.

These findings are thought to create significant obstacles for bringing this drug to market in 2017.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Alendronate Use in Steroid Treated Patients Lowers the Risk of Hip Fracture

 

Among older patients using medium to high doses of the anti-inflammatory steroid prednisolone, treatment with the osteoporosis drug alendronate was associated with a significantly lower risk of hip fracture, according to a study published by JAMA.

Potential Reasons Why Osteoarthritis Preferentially Affects Women

Researchers from Augusta University have examined exosomes from patients with knee osteoarthritis (OA) to enhance our molecular understanding of the pathogenesis of OA. (Citation source http://buff.ly/2tuDZ3v)

Bone Turnover Markers in Practice: A Guide for the Rheumatologist

Bone turnover markers (BTMs) have been eyed for decades as potential monitoring tools in osteoporosis.

However, there have been difficulties with poor between-lab reproductivity, insufficiently controlled heterogeneity, and pre-analytical variability of the assays; making BTMs vastly unpopular amongst practicing rheumatologists.

2017 ACR Guideline on Glucocorticoid-Induced Osteoporosis

The American College of Rheumatology has updated its 2010 guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. The guideline provides recommendations on assessing fracture risk and treatment for adults and special patient populations, including women of childbearing potential, adults treated with very high-dose glucocorticoids, adults with organ transplants, and children ages 4-17.

Higher Fracture Risks with Prolonged Bisphosphonate Use in Older Women

The Journal of the American Geriatric Society has reported that older women receiving bisphosphonate therapy for greater than 10-13 years were more likely to suffer from fractures.